Condition
Superior Limbic Keratoconjunctivitis
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Unknown3
Clinical Trials (3)
Showing 3 of 3 trials
NCT03731624UnknownPrimary
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders
NCT02160327UnknownPrimary
The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye
NCT00167050UnknownPrimary
The Pathogenesis of Superior Limbic Keratoconjunctivitis
Showing all 3 trials